Purpose We examined safety outcomes of interest (SOI) and overall survival (OS) among
lung cancer patients initiating crizotinib and erlotinib in routine clinical practice. Methods …

Introduction This phase I trial was conducted to determine the safety, maximum tolerated
dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients …

Background c-Met expression is common in NSCLC tumors and has been implicated in the
development of resistance to EGFR inhibitors. Criz is an ALK and MET/HGF receptor …

The past 7 years have seen dramatic changes in our understanding of the pathogenesis and
treatment of lung cancers. The clearest examples of these advances are erlotinib and …

Aug 1, 2016, marked World Lung Cancer Day. Lung cancer is one of the most common
cancers in the world, with 1· 8 million people diagnosed each year. While smoking is …

Lung cancer is the leading cause of cancer-related mortality in the United States, with
approximately 226,160 new cases of lung and bronchial cancer predicted to be diagnosed …

Abstract On December 11, 2015, the FDA granted accelerated approval to alectinib
(Alecensa; Genentech) for the treatment of patients with anaplastic lymphoma receptor …

Discoveries over the last decade have fundamentally transformed the way we define lung
cancer. Gone are the days of the simple binary classification system of non-small cell lung …

Aims: Premarketing clinical trials are typically conducted under controlled conditions and in
selected study populations, so real-world information on the utilization of new cancer drugs …

Purpose: We assessed the effect of baseline patient demographic and disease
characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume …